Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

NCT00036751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)